NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT04812002 2022-06-03Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined ChemotherapyWomen's Hospital School Of Medicine Zhejiang UniversityPhase 2 Recruiting20 enrolled
NCT02549209 2022-03-02Pembro/Carbo/Taxol in Endometrial CancerBig Ten Cancer Research ConsortiumPhase 2 Completed46 enrolled 13 charts